SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Isotechnika
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (77)6/2/2003 9:51:51 PM
From: teevee   of 285
 
Icebrg,
The side effects mentioned in the abstract for the renal trial results were not mentioned in the psoriasis trial results. I wonder if they are related to switching from Neoral to ISAtx247, other drugs in the coctail in combination with ISAtx247, or could it be due to the length of the trial as the psoriasis trial was of shorter duration? Also, as reported from the psoriasis trial, ISAtx247 has minimal effect on blood pressure and lipids, and that these effects are less
than that of Cyclosporine. Perhaps we will hear more about the comparisons in the renal trial when full results are published.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News